仟源医药(300254) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥183,185,038.02, a decrease of 4.46% compared to ¥191,735,280.29 in the same period last year[5] - The net loss attributable to shareholders was ¥2,156,812.13, representing a 40.00% increase in losses from ¥1,540,598.15 year-on-year[5] - Total operating revenue for Q1 2023 was CNY 183,185,038.02, a decrease of 4.06% compared to CNY 191,735,280.29 in Q1 2022[23] - Net profit for Q1 2023 was CNY 2,981,088.59, a decline from CNY 3,850,295.44 in Q1 2022[24] - The total comprehensive income for the period was CNY 2,981,088.59, compared to CNY 3,850,295.44 in the previous period[25] - The company's basic and diluted earnings per share were both -¥0.0089, a decrease of 30.88% from -¥0.0068 in the same period last year[5] - The company reported a basic and diluted earnings per share of CNY -0.0089, compared to CNY -0.0068 in the previous period[25] Cash Flow and Liquidity - The net cash flow from operating activities was -¥6,564,702.62, a decline of 120.37% compared to a positive cash flow of ¥32,222,075.16 in the previous year[5] - The company reported a net cash flow from operating activities of CNY -6,564,702.62, a significant decrease from CNY 32,222,075.16 in the previous period[28] - Cash inflow from operating activities totaled CNY 195,669,573.00, down from CNY 237,810,837.66 year-over-year[27] - The balance of cash and cash equivalents at the end of the reporting period was ¥343,318,600, an increase of 30.07% due to the receipt of a ¥100,000,000 performance bond from asset sales[9] - The company reported a cash balance of CNY 343,318,562.95 as of March 31, 2023, up from CNY 263,945,639.30 at the beginning of the year, indicating a growth of approximately 30.1%[20] - Cash and cash equivalents at the end of the period amounted to CNY 341,918,562.95, an increase from CNY 114,720,149.01 at the end of the previous period[28] - The net cash flow from investing activities was CNY 94,530,117.73, a turnaround from CNY -8,937,432.09 in the previous period[28] - The total cash outflow from financing activities was CNY 10,892,491.46, compared to CNY 12,169,773.54 in the previous period[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,644,516,932.21, an increase of 3.80% from ¥1,584,324,080.78 at the end of the previous year[5] - The company's total assets increased to CNY 1,644,516,932.21 in Q1 2023, up from CNY 1,584,324,080.78 in Q1 2022[22] - Total liabilities rose to CNY 911,856,123.42 in Q1 2023, compared to CNY 854,644,360.58 in the previous year[22] - The balance of prepayments decreased by 39.02% to ¥13,088,600, primarily due to reduced advance payments for goods[9] - Other non-current assets increased by 142.45% to ¥2,246,200, mainly due to increased advance payments for long-term asset purchases[9] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 19,008[13] - The total number of restricted shares at the end of the period was 17,985,699, with no shares released during the reporting period[16] - The top ten unrestricted shareholders hold a total of 50,000,000 shares, with the largest shareholder holding 15,772,409 shares[14] Strategic Initiatives - The company completed the election of the fifth board of directors and management team, appointing key personnel including Huang Lequn as chairman and Zhao Qun as president[17] - The subsidiary Jiangsu Jiayi Pharmaceutical Co., Ltd. received drug registration certificates for two new products, indicating ongoing product development efforts[17] - The company signed an asset sale framework agreement with Shanxi Shuangyan Pharmaceutical Co., Ltd. to optimize asset structure and reduce operational costs[18] - The company’s subsidiary Sichuan Qianyuan Traditional Chinese Medicine Co., Ltd. received a high-tech enterprise certificate, enhancing its market position[18] - The company aims to centralize production to lower costs and improve profitability, aligning with its strategic goals[18] - The company’s financial strategy includes avoiding large-scale fixed asset investments while enhancing operational efficiency through asset optimization[18] Operating Costs and Expenses - Total operating costs for Q1 2023 were CNY 185,981,096.81, down 7.26% from CNY 200,523,656.60 in the same period last year[23] - The company reported a decrease in sales expenses to CNY 76,345,934.29 in Q1 2023, down from CNY 94,256,873.49 in Q1 2022[23] - Research and development expenses for Q1 2023 were CNY 8,927,664.99, a decrease of 5.5% from CNY 9,449,694.89 in Q1 2022[24]